

SIRT and CS-PHP for Metastasized Uveal Melanoma: A Retrospective Comparative Study

Medical Affairs

Kolb et al.

- Year: 2023
 - Lead author: Dr. Manuel Kolb, Interventional Radiologist (Uni Tübingen)
 - Type of study: retrospective, comparative, single institution
 - Dates of period: December 2013 – February 2020, follow up period ended 21 September 2021
 - Patient cohort: 62 mUM (n = 34 with SIRT, receiving 41 cycles; n = 28 with CS-PHP, receiving 56 cycles)
 - Aim: Compare the outcome of patients treated with either SIRT or CS-PHP
-
- <https://www.mdpi.com/2072-6694/15/20/4942>

Kolb et al.

Patient selection and baseline characteristics




Figure 1. Flow chart of patient selection.

Table 1. Patient characteristics, including treatments.

	SIRT	CS-PHP
Number of patients	34	28
Age in years (mean \pm SD)	71 \pm 10	63 \pm 13
Female sex	15 (44%)	18 (64%)
Pre-treatment	liver-targeted	6 (18%)
	systemic total	10 (29%)
	chemotherapy	4 (12%)
	immunotherapy	6 (18%)
Extrahepatic metastasis at baseline		19 (68%)
	0–25%	26 (76%)
	26–50%	8 (24%)
Hepatic load		4 (14%)
	>50%	0
		0
Total number of cycles of SIRT/CS-PHP		56
	systemic total	16 (47%)
	chemotherapy	2 (6%)
	immunotherapy	14 (41%)
	other systemic	0
Post-treatment		2 (7%)
		5 (19%)
		17 (61%)
		0

Kolb et al.

Response (DCR)

- By standardized evaluation of tumor response according to the RECIST 1.1
- a disease control rate (**DCR**): of **18%** for SIRT and in **30%** for CS-PHP.

Kolb et al.

Results: OS

- Significant difference in OS
- SIRT: **9,90** months vs CS-PHP: **16,96** months
- HR = 0,46; CI 95% = (0,23; 0,93); p = 0,030




Figure 3. Kaplan–Meier graph of overall survival in days (moderated estimation).

Table 5. Overall survival of the study population from the timepoint of study.

OS in Days	Estimation	SIRT	CS-PHP
		mean ± SD	628.71 ± 512.90
from treatment	moderate	409.94 ± 406.96	628.71 ± 512.90
		median (range)	516 (5–1836)
		300.5 (19–1912)	516 (5–1836)

Kolb et al.

Results: PFS

- Cox regression model of the moderate calculations
- **no** significant difference between SIRT and CS-PHP
- HR= 0,59, CI 95%: (0,34; 1,02), p= 0,057

Table 6. Progression-free survival from the timepoint of study treatment.

PFS in Days	Estimation		SIRT	CS-PHP
from treatment	moderate	mean ± SD	303.88 ± 392.28	527.71 ± 473.43
		median (range)	127.5 (19–1912)	408.5 (3–1809)

Kolb et al.

Conclusion

- data have to be interpreted within its setting of a retrospective single center study
- This study demonstrates a possible small benefit of CS-PHP over SIRT in patients with **liver-dominant** mUM especially **concerning overall survival**
- It also shows the eminent need for prospective randomized trials, particularly to find the optimal **sequencing of liver-directed therapies,**
- Tebentafusp and immunotherapies or a **sequence** of these therapies